地尔硫(艹卓)革治疗缺血性心肌病患者心绞痛疗效观察

目的探讨口服地尔硫治疗缺血性心肌病(ICM)患者心绞痛(ICM-AP)的临床疗效。方法72例ICM-AP患者随机分为两组,对照组30例给予常规抗心绞痛、纠正心衰治疗,地尔硫组42例在以上常规治疗基础上给予地尔硫15~30 mg,每日4次,分别于9:00、15:00、21:00、3:00时间点口服,疗程2周。对比观察两组心绞痛改善程度和心电图变化,以及药物对心率、血压和心功能的影响。结果地尔硫组治疗心绞痛的临床总有效率高于对照组(P<0.05),两组心功能改善等级比较差异无统计学意义(P>0.05),两组血压比较差异无统计学意义(P>0.05),地尔硫组心率低于对照组(P<0.05)。结论口服地尔硫治疗ICM-AP安全有效。

Curative effect of diltiazem for treatment of patients with ischemic cardiomyopathy and angina pectoris

Objective To investigate the clinical efficacy of taking diltiazem orally for patients with ischemic cardiomyopathy and angina pectoris.Methods Seventy-two patients with ischemic cardiomyopathy and angina pectoris were randomly divided into two groups.Thirty patients in control group were treated with normal ways and means,42 patients in diltiazem group were given diltiazem 15-30 mg orally every 6 hours for two weeks,on the basis of normal treatment.The symptom,electrocardiogram,heart rate,blood pressure and heart function were observed in two groups.Results The clinical total effective rate was higher in diltiazem group than that in control group(P<0.05).There was no obvious difference in blood pressure and heart function between the two groups(P>0.05).The heart rate in diltiazem group was lower than that in control group(P<0.05).Conclusion Taking diltiazem orally for patients with ischemic cardiomyopathy and angina pectoris is effective.